Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
Amber WellerJohn GleesonMario Alvarez-JimenezPatrick McGorryBarnaby NelsonKelly AllottSarah BendallCali BartholomeuszPeter KovalSusy HarriganO'Donoghue BrianAlex FornitoChristos PantelisG Paul AmmingerAswin RatheeshAndrea PolariStephen J WoodKristi van der ElCarli EllinghausJesse GatesJessica O'ConnellMarianne MuellerLex WunderinkEóin KillackeyPublished in: Early intervention in psychiatry (2018)
This study will provide evidence as to whether an antipsychotic dose-reduction recovery treatment leads to improved functioning and safer outcomes in first-episode psychosis patients. In addition, it will be the first-controlled experiment of the effect of exposure to antipsychotic maintenance treatment on brain volume changes in this population.
Keyphrases
- study protocol
- end stage renal disease
- clinical trial
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- multiple sclerosis
- prognostic factors
- combination therapy
- white matter
- metabolic syndrome
- subarachnoid hemorrhage
- phase iii
- cerebral ischemia
- placebo controlled